CASE REPORT

Genotype–Phenotype correlations of SCARB2 associated clinical presentation: a case report and in-depth literature review

Burcu Atasu1,2*†, Ayse Nur Oezdag Acarli3†, Basar Bilgic3, Betul Baykan5, Erol Demir4, Yasemin Ozluk5, Aydin Turkmen4,6, Ann-Kathrin Hauser1,2, Gamze Guven7, Hasmet Hanagasi3, Hakan Gurvit3, Murat Emre3, Thomas Gasser1,2 and Ebba Lohmann1,2

Abstract

Background: Biallelic pathogenic variants in the SCARB2 gene have been associated with action myoclonus-renal failure (AMRF) syndrome. Even though SCARB2 associated phenotype has been reported to include typical neurological characteristics, depending on the localization and the feature of the pathogenic variants, clinical course and the presentations have been shown to differ.

Case presentation: Whole exome sequencing (WES) analysis revealed a homozygous truncating variant (p.N45MfsX88) in SCARB2 gene in the index case, and subsequent sanger sequencing analysis validated the variant in all affected family members from a Turkish family with the clinical characteristics associated with AMRF and related disorders. Intrafamilial clinical heterogeneity with common features including dysarthria, tremor and proteinuria, and distinct features such as peripheral neuropathy (PNP), myoclonus and seizures between the affected cases, was observed in the family.

In-depth literature review enabled the detailed investigation of the reported variants associated with AMRF and suggested that while the type of the variant did not have a major impact on the course of the clinical characteristics, only the C terminal localization of the pathogenic variant significantly affected the clinical presentation, particularly the age at onset (AO) of the disease.

Conclusions: In this study we showed that biallelic SCARB2 pathogenic variants might cause a spectrum of common and distinct features associated with AMRF. Of those features while the common features include myoclonus (100%), ataxia (96%), tonic clonic seizures (82%), dysarthria (68%), tremor (65%), and renal impairment (62%), the uncommon features involve PNP (17%), hearing loss (6.8%), and cognitive impairment (13.7%). AO has been found to be significantly higher in the carriers of the p.G462DfsX34 pathogenic variant.

SCARB2 pathogenic variants have not been only implicated in AMRF but also in the pathogenesis of Parkinson's disease (PD) and Gaucher disease (GD), suggesting the importance of genetic and functional studies in the clinical and the diagnostic settings.

*Correspondence: brcdursun@hotmail.com
†Burcu Atasu and Ayse Nur Ozdag Acarli contributed equally to this work as the first authors.
1 Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Given the proven role of \textit{SCARB2} gene in the pathogenesis of AMRF, PD and GD with a wide spectrum of clinical symptoms, investigation of the possible modifiers, such as progranulin and HSP7, has a great importance.

\textbf{Keywords:} SCARB2, Action Myoclonus-Renal Failure Syndrome, Progressive Myoclonic Epilepsy, Gaucher disease, Parkinson’s disease, Ataxia, Pathogenic variants

\section*{Background}

Action myoclonus-renal failure syndrome (AMRF; MIM 254,900) is a rare autosomal recessive inherited disorder with progressive neurological and renal symptoms. The disease usually presents in the first two decades of the life, and some patients do not develop renal failure in the course of the disease. Neurologic manifestations can appear before, simultaneously, or after the renal manifestations and include myoclonus, epileptic seizures, ataxia, tremor, peripheral neuropathy, hearing loss and behavioral problem, whereas renal symptoms consist of proteinuria and kidney failure. AMRF was first described in four French Canadian patients whose symptoms were myoclonus, cerebellar symptoms, and proteinuria [1, 2]. Recently, loss-of-function pathogenic variants in \textit{scavenger receptor class B member 2} gene (\textit{SCARB2}), which encodes lysosomal integral membrane protein type 2 (LIMP-2) protein [3, 4] have been identified in AMRF patients [5]. LIMP-2 is an abundant, highly glycosylated lysosomal membrane protein that plays a pivotal role in the delivery of \(\beta\)-glucocerebrosidase (GC) to lysosomes [4]. GC is required for lysosomal hydrolysis of glucosylceramide and is targeted to lysosomes in a mannose-6 phosphate-independent manner by LIMP-2 [6]. LIMP-2 and GC interact in the endoplasmic reticulum (ER), and the two proteins traverse Golgi and endocytic compartments together en route to lysosomes, at which the acidic pH facilitates dissociation of GC from LIMP-2 [4, 6]. \textit{SCARB2} pathogenic variants lead to accumulation of the LIMP-2 protein in the ER, thereby leading to missorting and lysosomal depletion of GC [6]. Decreased lysosomal activity of GC is also seen in GD, the most common lysosomal storage disease caused by the homozygous pathogenic variants in the gene encoding GC, as well as in PD, of which \textit{SCARB2} is a risk conferring gene. Deficient activity of GC was observed in cultured skin fibroblasts of AMRF patients [7].

\textit{SCARB2} associated phenotype has been shown to include a wide spectrum of neurological characteristics with varying AO depending on the localization of the pathogenic variants. (Table 2). By taking the advantage of WES strategy, in this study we investigated the underlying genetic cause of a consanguineous Turkish family with five siblings presenting with neurological and renal symptoms, compared our findings to the literature and developed a genotype–phenotype correlation based on the reported cases with \textit{SCARB2} pathogenic variants.

\section*{Case presentation}

**Individual II.8** is a 31-year-old male with normal motor and mental development and had no medical problems until the age of 22 years when he developed speech problems and behavioral changes such as irritability and depressed mood. At the age of 24 years tremor in his hands and mild gait instability added to the clinical picture. One year later myoclonic jerks triggered by noise, mental tasks and stress and generalized tonic–clonic seizures appeared. At the age of 26 years proteinuria was detected in his routine exams. He was admitted to the Outpatient Clinic of Neurology Department of Istanbul University when he was 28 years old. In his neurological examination, significant myoclonic movements in his limbs, trunk, and the lower facial muscles mostly appearing with the movements of the limbs were observed, and jerks were sensitive to touch. There were also jerky movements with a relatively small amplitude in the rest position. He had hesitations of speech and dysarthria due to bulbar and palatal myoclonus. He presented prominent gait instability due to ataxia and high amplitude myoclonic movements (see supplementary file, Video_1.mov and Video_2.mov). Cognitive testing showed impairment in executive functions and attention. The patient was depressed (Beck’s Depression Inventory 21/30). Serum creatinine was in a normal range and 24-h urine protein level was 3540 mg. Magnetic resonance imaging (MRI) of the brain and peripheral nerve conduction velocity (NCV) were normal. Long latency reflexes and giant somatosensory evoked potentials (SEP) were recorded. The electroencephalography (EEG) findings showed 3–4 Hz generalized epileptiform abnormalities, a broad range of photosensitivity (during 5–24 Hz intermittent photic stimulations), as well as diffuse background slowing of theta range. Ictal spike-wave discharges were recorded corresponding to the myoclonic jerks. His audiometry was normal. Abdominal ultrasound showed increased cortical echogenicity of the kidneys bilaterally (suggesting renal parenchymal disease) and mild splenomegaly.

Kidney biopsy showed nine glomeruli, one of which was globally sclerotic. Segmental sclerotic lesion was
observed in one glomerulus, and immunofluorescence microscopy demonstrated segmental deposition of IgM in capillary loops. Biopsy findings were compatible with a diagnosis of focal segmental glomerulosclerosis (FSGS). Collapsing features of segmental sclerosis were partially present. Transmission electron microscopic evaluation was demonstrated food process effacement with osmophilic irregular conglomerate electron-dense inclusions within endothelial and tubular cell cytoplasm. Some inclusions were filamentous, lamellar, and rectilinear in structure.

He was put on zonisamide (200 mg/day), piracetam (9600 mg/day), clonazepam (2 mg/day) and losartan (100 mg/day). Antiepileptic drugs had a limited beneficial effect on generalized seizures. However, myoclonic movements did not respond to treatment. The patient stopped all his treatments at the age of 29 except for losartan. His symptoms worsened over time, and he accepted to use Miglustat (300 mg/day), but after a month he discontinued the treatment due to severe exacerbation of action myoclonus and ataxia.

Initial symptoms of the individual II.9 were irritability, speech impairment, tremor, and myoclonic movements started at the age of 21 years. Two years later cerebellar ataxia and generalized seizures added, and he admitted for the first time to the neurology department when he was 27 years old. Neurological examination revealed dysarthria with speech induced bulbar myoclonus and there were severe myoclonic movements in his distal parts of the limbs as well as in his trunk. Myoclonic jerks were significant especially when he was moving his upper extremities and when he was speaking. However, some jerky movements were also present in the resting position. Gait was severely impaired by both vigorous myoclonic movements and cerebellar involvement. Although the patient had no cognitive complaints, the neuropsychological assessment showed impairment in executive functions and attention, similar to his elder brother (individual II.8).

Results of routine biochemistry were in the normal limits. The 24-h urine protein level was 336 mg/day. MRI of the brain and whole medulla spinalis revealed normal. Peripheral nerve conduction velocity was normal, but long latency reflexes were recorded in the SEP. The EEG showed generalized epileptiform abnormalities as well as diffuse slowing of the background activity. His audiometry was normal. He was treated with valproic acid (maximum dose 2000 mg/day), levetiracetam (maximum dose 2500 mg/day), piracetam (maximum dose 4800 mg/day) and clonazepam (maximum dose 3 mg/day) but no significant effect was noticed. Myoclonic movements and ataxia worsened overtime, and he became bedridden. He developed dysphagia which led to aspiration pneumonia, and he died because of septicemia when he was 28 years old.

Individual II.10 was complaining about mild and rare twitches in the perioral muscles, and mild tremor in his hand started a year ago. In his neurological examination he had mild dysarthria, and there were rare speech-induced myoclonic movements in his bulbar muscles as well as mild tremor in his hands. He had no other myoclonic movements and no ataxia was observed. Serum and urine laboratory results were in normal limits except for proteinuria (515 mg/day). Brain MRI and electrophysiological examinations including peripheral NCV and SEP were normal. Concentric needle electromyography (EMG) of the proximal and distal muscles showed large-amplitude polyphasic motor unit potentials and wide-spread decreased recruitment of motor units without spontaneous activity. No epileptiform activity or slowing was seen in his EEG.

Mild myoclonic movements appeared in individual II.12 when he was 8 years old. At the age of 16, generalized seizures along with tremor, and speech problems were added to the clinical picture and two years later he developed ataxia. He admitted to our department when he was 21 years old, and in his neurological examination, there were dysarthria and ataxia, and myoclonic movements worsening with motor activity in his perioral muscles and extremities. He had also increased levels of urinary protein (500 mg/day). MRI of the brain was normal. Although the peripheral NCV was in the normal limits, concentric needle EMG of the proximal and distal muscles showed large-amplitude polyphasic motor unit potentials and widespread decreased recruitment of motor units without spontaneous activity. In his SEP examination, stimulation of the median nerve elicited normal responses however prolonged latency of the cortical P37 was recorded with the tibial nerve stimulation. The EEG showed no abnormality, and his audiometric evaluation was normal. Abdominal ultrasound examination showed findings of low-grade fatty liver with increased liver echogenicity. He was treated with valproic acid (maximum dose 1000 mg/day), and levetiracetam (maximum dose 1000 mg/day). He was put on Miglustat (100 mg/day), but in the first week of the treatment, he refused to use the drug due to worsening of myoclonic movements and ataxia.

Individual II.13 was admitted to the hospital with complaints of typhoid fever. Nephrotic range proteinuria (9631 mg/day) was detected in his laboratory results. He had no myoclonic movements, ataxia or epileptic seizures. He underwent a renal biopsy, and it showed FSGS. Immunofluorescence microscopy showed deposition of
one positive C1q, C3, and IgM in capillary loops. Even he had no neurological complaint, at the time of the assessment of all family members, it was noticed that he had mild difficulty in speech and mild tremor in his hands. Sensory loss and impaired vibration sensation were noticed in the distal part of the extremities with normal deep tendon reflexes. The EMG revealed a mild axonal type of sensorimotor neuropa thy. Serum vitamin B12 level was found to be decreased, and he was put on replacement treatment. The EEG and cranial MRI revealed normal.

In this study, consistent with the previously reported renal biopsy findings renal biopsy showed tubular abnormalities in the distal and collecting tubules with isometric vacuolization. In addition, there were FSGS (with collapsing glomerulopathy) and the deposition of granular material in cortical tubules, and glomeruli without inflammatory infiltration. These findings were compatible with FSGS with non-specific immunoglobulin and complement trap. There was osmophilic irregular conglomerate electron-dense inclusions in the glomerulus in the individual II.8, which could be further investigated to provide with more insight into the renal involvement of the disease.

To uncover the genetic cause of the clinical presentation observed in the family 1, WES analysis was performed in the index case (II.8) by following the same workflow described elsewhere [8]. Consistent with the pedigree information inbreeding coefficient (F) was found to be “0.1162” (for a first cousin marriage $F \geq 0.0625$), confirming the consanguinity in the family. WES analysis revealed a homozygous truncating variant (p.N45MfsX88) in SCARB2 gene in the index case (II.8). Subsequent Sanger sequencing analysis identified the same homozygous variant in the other affected individuals (II.9, II.10, II.12, II.13), whereas all unaffected family members were either heterozygot (I.1, I.2 II.3, II.4, II.7, II.11) or non-carrier (II.1, II.2, II.5, II.6) (Fig. 1).

**Summary and clinical comparison of the cases with SCARB2 p.N45MfsX88 pathogenic variant**

In this study, we describe a multiple affected ($n=5$) consanguineous Turkish family with a homozygous truncating pathogenic variant (c.134delA; p.N45MfsX88), which has recently been reported in an independent Turkish family [9] (family 2) in the SCARB2 gene presenting with similar clinical presentation with slightly different AO of the disease and without dysarthria and cognitive impairment (Table 1).

In the family 1 the cardinal clinical features shared in all the affected individuals are dysarthria, tremor and proteinuria, other features such as PNP, myoclonus and seizures are only observed in some of the affected members (Table 1). In general, all the clinical features except for dysarthria and cognitive decline are shown to be comparable with the second family also originating from Turkey and harboring the same pathogenic variant (Table 1). This report also shows that the same SCARB2 pathogenic variant can cause intra-clinical heterogeneity including different AO of the symptoms having a range from 8 to 23 years.

Neuropsychological testing revealed executive dysfunction and attention deficit in two patients (II.8 and II.9) of family 1, however, no cognitive dysfunction was reported in the family 2.

**Literature review of reported cases with SCARB2 pathogenic variants**

The Medline and the human mutation database [10] were searched using terms as SCARB2, CD36L2 and LIMP2. All the reported pathogenic variants in SCARB2 gene were reviewed in terms of clinical and genetic characteristics. We classified the variants based upon if those have been associated with AMRF (Table 2) or not directly AMRF (Table 3).

**SCARB2 pathogenic variants associated with AMRF**

To date, 26 distinct pathogenic variants including nonsense ($n=4$), splice site ($n=9$), frameshift ($n=12$),
**Table 1** Clinical characteristics of the cases with the SCARB2 p.N45MfsX88 Pathogenic Variant

| ID  | Gender | Age at onset of symptoms (years) | Deceased | Imaging | EEG | EMG | Mental status |
|-----|--------|----------------------------------|----------|---------|-----|-----|---------------|
|     |        | Dysarthria | Tremor | Myoclonus | Seizures | Renal Involvement | Age (y) | Cause |       |
| Family 1 |       |               |          |          |          |                 |         |        |       |
| II.8 | M      | 22            | 24      | 25       | 25       | 26              | -       | Normal brain MRI | BGS, PS, GSW | Normal NCV/SEP, Long latency reflexes and giant SEP | Impaired executive functions/attention |
| II.9 | M      | 21            | 21      | 21       | 23       | 27              | 28      | Aspiration pneumonia | Normal brain and spinal MRI | BGS, ECS, GSW | Normal NCV/SEP, Long latency reflexes |
|      |        |               |          |          |          |                 |         |        | Irritability, impaired executive functions/attention |
| II.10 | M      | 25            | 25      | -        | -        | 25              | -       | Normal brain MRI | Normal | Normal NCV/SEP, Polyphasic MUPs and widespread decreased recruitment of motor units without spontaneous activity |
|      |        |               |          |          |          |                 |         |        | NR |
| II.12 | M      | 19            | 17      | 8        | 16       | 19              | -       | Normal brain MRI | Normal | Normal NCV/SEP, Polyphasic MUPs and widespread decreased recruitment of motor units without spontaneous activity |
|      |        |               |          |          |          |                 |         |        | NR |
| II.13 | M      | 20            | 20      | -        | -        | 16              | -       | Normal brain MRI | Normal | Normal NCV/SEP, Polyphasic MUPs and widespread decreased recruitment of motor units without spontaneous activity |
|      |        |               |          |          |          |                 |         |        | NR |
| Family 2 |       |               |          |          |          |                 |         |        |       |
| Case 1 | M      | NR            | 17–18   | 18–19    | 18–19    | +               | -       | Normal brain MRI | GSW | Sensorimotor axonal neuropathy |
| Case 2 | F      | NR            | 23      | 24       | 24       | +               | -       | Normal brain MRI | GSW | Normal |

This table indicates the clinical characteristics of the family 1 and the family 2 [9] harboring the same pathogenic variant (p.N45MfsX88) reported from Turkey. Family 1 is described in this study and family 2 was recently published by Uçan Tokuç et al. [8]. BGS background slowing, PS photosensitivity, GSW generalized spike-wave, ECS eye closure sensitivity, NCV nerve conduction velocity, SEP somatosensory evoked potential, MUP motor unit potential, y years, M male, F female, NR not reported, MRI magnetic resonance imaging.
| Genetic findings | Clinical characteristics | Type of the variant | Pathogenic Variant | Zygosity | Localization on the protein | Age at onseta | Age at deathb | Myoclonusa | Tremora | Ataxiaa | Dysarthriaa | Seizure | Renal involvement/FSGSa | PNP | Additional clinical manifestations | Reported families/affected individuals | Ethnicity | Ref |
|------------------|------------------------|---------------------|-------------------|----------|-----------------------------|--------------|--------------|-----------|---------|---------|-----------|--------|------------------------|-----|-----------------------------|-----------------------------|----------|-----|
| Nonsense c.533G > A; p.W178X | HM GC binding domain | 16±1.4 (15, 17) 25.5±2.3 (23, 26) 16±1.4 (15, 17) NR 17.5±0.7 (15, 18) + NR 19.5±2.1 (18, 21) | - | Slow motion saccadic eye movements | 1/2 | Portugal [7] |
| Splicing c.1239+1G > T | HM Lumenal domain | 22 NR 32 25 32 32 NR 28/+ | - | NR | 1/1 | Turkish-Cypriot [5] |
| Frameshift c.435_436insAG; p.W146SfsX16c | HM Lumenal domain | 9 32 29 21 + + + NR NR 19.5±2.1 | - | NR | 1/1 | Scottish [5] |
| Frameshift/Splicing c.296delA; p.N99fsX34 | HM Lumenal domain/Lumenal domain | 19 NR 24 19 26 26 + 20/NR | NR NR 1/1 | British [5] |
| Nonsense c.862C > T; p.Q288Xc | HM GC binding domain | 20±4.4 (17, 18, 23) 297±5 (29, 25, 33) 23±2 (21,23,25) 20±4.4 (17, 18, 25) + + + 22.5±0.7/NR (17, 18, 30) NR NR 1/3 | French Canadian [5] |
| Missense c.1087C > A; p.H363N | HM Lumenal domain | 26 NR 26 NR 27 NR + - - NR 1/1 | NR | 1/1 | Italian [11] |
| Splicing c.1116+2A > C | HM Lumenal domain | 14 29 14 NR 17 NR | + 15/NR NR NR 1/1 | Italian [12] |
| Splicing c.704+1G > C | HM Lumenal domain | 15 27 15 NR 16 NR + 12/NR NR NR 1/1 | Italian [12] |
| Frameshift c.1258delG; p.E420RfsX5 | HM Lumenal domain | 23 33 23 NR 24 NR + 10/NR NR NR 1/1 | Italian [12] |
| Frameshift c.666delCTTA; p.Y222X | HM Lumenal domain | 25 40 25 NR 31 NR + 15/NR NR NR 1/1 | Italian [12] |
| Splicing/Missense c.424-2A > C; c.108P>A; p.H363N | HM Lumenal domain/Lumenal domain | 5.5 NR 26 26 26 NR + 5.5/NR NR NR 1/1 | Italian [12] |
| Nonsense c.862C > T; p.Q288Xc | HM GC binding domain | 16 NR 16 NR NR + + + | + NR 1/1 | French Canadian [5] |
| Frameshift c.111delC; p.I37MfsX7 | HM Lumenal domain | 18±3.6 (14, 20, 20) 34.3±3.5 (31, 34, 38) 20±6 (14, 20, 26) NR 18±3.6 (14, 20, 20) NR + +/NR + Hearing impairment, dilated cardiomyopathy | 1/3 | German [14] |
| Splicing c.704+1G > A | HM Lumenal domain | 21 NR 23 23 21 25 + 25/NR NR Hearing loss | 1/1 | Australian [15] |
| Frameshift c.1385_1390delinsATG | HM TM domain | 46.6±4.7 (43, 52, 49) + (NR, NR, NR) 52±13.8 (43, 68, 45) + (NR, 57, 48) 48.3±4.6 (44, 52, 49) 50±6.5 (44, 57, 51) + (58, 63, NR) +vNR NR | 1/1 | Japanese [17, 18] |
| Nonsense c.361C > T; p.R121X | HM Lumenal domain | 20 28 20 + + + + - - Cognition impairment | 1/1 | Japanese [18] |
Table 2 (continued)

| Genetic findings | Clinical characteristics | Type of the variant | Zygosity | Localization on the protein | Age at onseta | Age at deathb | Myoclonusb | Tremorb | Ataxiab | Dysarthria | Seizure | Renal involvement/ FSGSa | PNP | Additional clinical manifestations | Reported families/ affected individuals | Ethnicity Ref |
|------------------|--------------------------|---------------------|----------|-----------------------------|---------------|---------------|-------------|---------|---------|------------|---------|------------------------|-----|----------------------|-------------------------------|-------------|
| Nonsense c.1270C > T; p.R424X | HM homozygote | Lumenal domain | 20.5 ± 4.7 (17, 17, 21, 27) | + | + | + | + | +/NR | NR | Mild generalized skeletal muscle atrophy (34) | 19 | 24 | [19, 20] |
| Splicing c.995-1G > A | HM homozygote | Lumenal domain | 20.5 ± 0.7 (21, 20) | NR | 20.5 ± 0.7 (21, 20) | NR | 20.5 ± 0.7 (21, 20) | + | + | - | NR | Pes cavus, Mild generalized skeletal muscle atrophy | 1/2 | Chinese | [21] |
| Splicing c.1187+5G > T | HM homozygote | Lumenal domain | 19 NR | 19 | 19 | 19 | 19 | + | + | - | + | NR | 1/1 | Chinese | [22] |
| Frameshift p.L144PfsX35 | HM homozygote | TM domain | 19 NR | 19 | 19 | 19 | 19 | + | 27 | + | +/NR | NR | NR | 1/1 | Arab | [23] |
| Frameshift c.134delA; p.N45MfsX88 | HM homozygote | Lumenal domain | 20±4.2 (17, 23) | NR | 21.5 ± 3.5 (19, 24) | 20±4.2 (17, 23) | + | NR | + | +/NR | NR | NR | 1/2 | Turkish | [9] |
| Frameshift/ Splicing c.434_435dup/ c.704_+5G > A | CH compound heterozygote | Lumenal domain/ Lumenal domain | 19 NR | 19 | 19 | 19 | 19 | + | NR | - | +/NR | NR | NR | 1/1 | British or Irish | [24] |
| Frameshift p.L319X6X | HM homozygote | Lumenal domain | 27 NR | 27 | + | + | + | 30 | 30 | 30 | - | - | NR | NR | 1/1 | Gambian | [25] |
| Splicing c.423_+1G > A | HM homozygote | Lumenal domain | 20.5±2.1d (22, 19) | NR | 32±2.8d (34, 30) | 20.5±2.1d (22, 19) | 33±1.4d (34, 32) | 40.5±6.3d (36,45) | + | 40.5±6.3d (36,45) | ANR | NR | NR | 1/6 | Iranian | [26] |
| Frameshift / Nonsense c.435_436insAG; p.L146fsX16c/ c.862C > T;p.Q288Xc | CH compound heterozygote | Lumenal domain / GC binding domain | 20 NR | 23 | NR | 23 | 22-23 | 20 | ± | NR | Unilateral uretero‑pelic junction | 1/1 | French Canadian/ Irish English | [27] |
| Frameshift c.134delA; p.N45MfsX88 | HM homozygote | Lumenal domain | 18.4±6.7 | 28(19) | 18±8.9 | 214±3.2 | 199±6.2 | 214±2.3 | + | 28(19)/+ | 21 (30) | Irritability, impaired executive functions/ attention | 1/5 | Turkish | Present study |

This table indicates the genetic and clinical features of the reported families associated with AMRF. aAverage age at onset was indicated, in case of more than one carriers of the same mutation have different ages at onset. In case of only one affected from a family, age at onset of symptoms corresponding to that individual was indicated. When available, age at onsets of all the individuals were indicated in parenthesis. bAverage age at death was indicated, in case of more than one carriers of the same mutation have different ages at death. When available, age at deaths of all the individuals were indicated in parenthesis. cFounder mutation. dThe average age at onsets were indicated based on the clinical information of two reported individuals (IV.9, IV.12). eWhen the average age at onsets could not be calculated, only the onsets of the corresponding symptoms for each individual were indicated. fThe possibility of second SCARB2 PV. NR: not reported in the corresponding study, -: not observed in the corresponding study, HM homozygote, CH compound heterozygote, H heterozygote, +: observed in the patients but not detailed information provided in the corresponding studies, ?: the correct nomenclature could not be found in the original study.
## Table 3  Clinical and Genetic Characteristics of the non-AMRF Associated Families

| Type of the variant | Pathogenic Variant | Zygosity | Localization on the protein | Clinical characteristics | Implication of the Variant | Reported families/affected individuals | Reference |
|---------------------|--------------------|----------|-----------------------------|--------------------------|----------------------------|---------------------------------------|-----------|
| Missense, de novo   | c.518 T > C;p.V173A| H        | GC binding domain           | ASD                      | Implication in chromatin     | 1/1                                   | [28]      |
|                     |                    |          |                             | modification, FMRP-associated mechanisms and embryonic development |
| Missense            | c.842 T > C;p.F281S| H        | GC binding domain           | SUDEP                    | Implication in the underlying mechanisms of SUDEP | 1/1                                   | [29]      |
| Missense            | c.914 C > T;p.Y305M| H        | Lumenal domain              | PS                      | Possible modifier in the PS  | 1/2                                   | [30]      |
| Nonsense            | c.1365; p.W455X    | CH       | Lumenal domain              | Epilepsy and neurodevelopmental disorders | Implication in the underlying mechanisms of epilepsy and neurodevelopmental disorders | 1/1       | [31]      |
| Frameshift          | c.434_435insAG; p.W146SfsX16 | CH       | Lumenal domain              | Possible modifier in the binding dependent mechanisms of LIMP-2 and GC | 1/2 | [32]      |
| Frameshift          | c.1412A > G;p.E471G| H        | TM domain                   | Gaucher disease, myoclonic epilepsy, dementia | Possible modifier in the binding dependent mechanisms of LIMP-2 and GC | 1/2 | [32]      |
| Frameshift          | c.1412A > G;p.E471G| H        | TM domain                   | Gaucher disease, myoclonic epilepsy, dementia | Possible modifier in the binding dependent mechanisms of LIMP-2 and GC | 1/2 | [32]      |
| Frameshift          | c.1337delG;p.G446VfsX48 | CH       | Lumenal domain              | Seizures                 | NR                         | 1/1                                   | [34]      |
| Frameshift          | c.434_435insAG; p.W146SfsX16 | CH       | Lumenal domain              | Seizures                 | NR                         | 1/1                                   | [34]      |

**Molecular and clinical details of the reported pathogenic variants associated with atypical clinical features.**

- The variant was associated with AMRF in a homozygous state.
- NR: Not reported in the corresponding study.
- **H:** homozygote, **CH:** compound heterozygote, **H:** heterozygote, **ASD:** autism spectrum disorder, **SUDEP:** sudden unexpected death in epilepsy, **PS:** Pendred syndrome.
missense \((n = 1)\) variants, have been reported in 48 cases from 29 independent families with AMRF from various ethnic groups. The mean AO and age at death were found to be 19.4 ± 6.9 and 30.6 ± 2.3, respectively. The clinical and the genetic characteristics of the reported families were summarized in the Table 2. The families have been reported from various ethnic groups \((n = 1)\) Portuguese, \(n = 1\) Turkish-Cypriot, \(n = 1\) Scottish, \(n = 2\) British, \(n = 3\) French-Canadian, \(n = 5\) Italian, \(n = 1\) German, \(n = 1\) Australian, \(n = 3\) Japanese, \(n = 2\) Arab, \(n = 2\) Chinese, \(n = 2\) Turkish, \(n = 1\) Gambian, \(n = 1\) Iranian). No population specific pathogenic variance distribution was observed.

Two of the previously reported pathogenic variants \((p.Q288X; p.W146SfsX16)\) have been shown to be founder variants in French-Canadian and Scottish populations [5, 13]. So far, only one pathogenic variant \((p.N455fsX88)\) in SCARB2 has been identified in the Turkish population besides the variant \((c.1239+1G > T)\) found in the Turkish-Cypriot population [5]. Therefore, it is highly possible that this particular variant \((c.134delA; p.N455fsX88)\) be a founder variant and this possibility could be further investigated by haplotype analysis.

The common clinical features observed in the AMRF patients harboring SCARB2 pathogenic variants include myoclonus \((n = 29)\), ataxia \((n = 28)\), tonic clonic seizures \((n = 24)\), dysarthria \((n = 20)\), tremor \((n = 19)\) and renal impairment \((n = 18)\), whereas the uncommon features of those involve PNP \((n = 5)\), hearing loss \((n = 2)\), and cognitive impairment \((n = 4)\).

The statistical analysis showed that only the C terminal localization of the pathogenic variant is significantly associated with the AO (Mann–Whitney U test, \(P < 0.001\)), however, neither the type of the pathogenic variant nor the domain localization of the pathogenic variant is associated with AO or age at death (Mann–Whitney U test, \(P > 0.05\)).

Cognitive decline has been reported only in four AMRF cases from three unrelated families [17, 18].

**SCARB2 pathogenic variants associated with non-AMRF**

SCARB2 variants have also been implicated in differential clinical conditions overlapping or not with the symptoms of AMRF (Table 3). In addition to the AMRF associated variants, seven distinct SCARB2 variants, including four missense, one nonsense, and two frameshift variants, have been identified. All the missense variants have been found in a heterozygous state while, nonsense and frameshift variants have been found either in homozygous or compound heterozygous state. Interestingly, two heterozygous variants \((c.914C > T;p.Y305M, c.1412A > G;p.E471G)\) have been reported to be possible modifiers in the Pendred syndrome (PS) [30], which is characterized by the combination of sensorineural deafness/hearing impairment, goiter, and an abnormal organification of iodide with or without hypothyroidism, and in GD pathogenesis [32]. In addition, two other variants \((c.518 T > C;p.V173A, c.842 T > C;p.F281S)\) have been suggested to be risk conferring variants in autism spectrum disorder [28] and sudden unexpected death in epilepsy [29]. Strikingly, of those variants, p.E471G was proposed as a possible indicator of the convergent disease mechanisms of the AMRF and GD. The remaining biallelic nonsense and frameshift variants were associated with the spectrum of AMRF symptoms, but their phenotype only included seizures, myoclonus, or cerebellar ataxia, suggesting the importance of the WES based approaches in the clinical-diagnostic settings.

**Discussion and conclusions**

Biallelic pathogenic variants in SCARB2 gene have been shown to cause AMRF with a wide spectrum of neurological and renal symptoms. SCARB2 gene encodes a type III transmembrane glycoprotein called LIMP-2. LIMP-2 consists of four domains, of which three are cytoplasmic (CT) and transmembrane (TM) domains, and one lumenal domain (residues 28–433) encompassing the GC binding site (residues 155–191, 178–288) [6] functioning in a pH dependent manner (Fig. 2–1). Genetic as well as the functional studies imply that disturbed LIMP-2 activity causes perturbed trafficking of GC and thereby leads to the retention of LIMP-2 in the ER and/or secretion to the extracellular space suggesting impaired targeting of the GC to the lysosomes (Fig. 2–3), which is also a pathomechanism implicated in GD and PD [35]. Investigation of the function of the LIMP-2 is therefore highly important in terms of shedding light on the convergent pathogenic mechanisms of the neurological diseases, such as AMRF, GD and PD (Fig. 2–6).

To date, different type of variants from various ethnic groups have been reported to be associated with AMRF. Interestingly, except for only one missense variant \((p.H363N)\), of all the reported variants are loss of function variants \((n = 25)\), which are supposed to lead to a truncation or total absence of the protein through nonsense mRNA-mediated decay in the cellular systems. However, even though the reported missense variant is not expected to cause such a harmful effect, the clinical picture of the patients carrying this missense variant is very similar to that of the carriers of the other truncating variants. Interestingly, functional studies on the mutant models suggested that while the binding affinity of LIMP-2 to GC has been perturbed in loss of function variant carriers \((p.W146SfsX16, p.W178X)\), it has been conserved in the missense variant carrier \((p.H363N)\).
as well as in one particular loss of function variant carrier (p.Q288X), where the essential binding site is preserved [6]. However, even though the binding property of LIMP-2 to GC has been shown to differ based on the type of the variant, the ER retention of LIMP-2 has been reported to be common in all four investigated variants [6]. These findings suggest that other mechanisms or modifiers might play a role in the pathogenicity of the disease and lead to a complex pathogenic mechanism. One of those possible implicated mechanisms is that progranulin couples heatshock-protein 70 (HSP70) to the GCCase/LIMP2 complex in the ER and leads the cargo of the GC to the lysosomes [36] (Fig. 2–2).

The majority of the reported pathogenic variants are localized in the luminal domain except for the two variants (p.L14PfsX35, p.G462DfsX34) which are localized in the TM domains. One of those (p.G462DfsX34) is reported to cause a milder phenotype with a later AO and the absence of renal involvement in three patients from two unrelated families originating from Japan [17, 18] (Table 2, Fig. 2–1). In addition, this variant has been found to be significantly associated with a higher AO. Compared to the carriers of other variants the difference of the p.G462DfsX34 phenotype has been attributed to the residual activity of the protein [17]. The other pathogenic variant (p.L14PfsX35) is localized in the N terminal site of the protein, and it is expected to cause a total loss of the luminal and C terminal TM domains. Therefore, its effect on the clinical severity is similar to the clinical presentation of patients carrying variants in the luminal domain.

Clinical characteristics of the reported pathogenic variant carriers have been shown to be common features such as myoclonus, ataxia, tremor, dysarthria, tonic clonic seizures, renal impairment and more rarely observed uncommon features including PNP, hearing loss, and cognitive impairment (Table 2). Interestingly, among those clinical features, cognitive impairment has only been shown in three particular variant carriers (p.G462DfsX34, p.R121X, p.N45MfsX88) originating from Japan and Turkey [17, 18]. Therefore, it is important to note that even the patients do not complain about cognitive functions, a detailed cognitive testing is required to detect subtle cognitive deficit in the
individuals with AMRF. Of those clinical characteristics PNP and hearing loss have been reported in the knock-out animal models [37].

Strikingly, some SCARB2 variants have not been directly associated with AMRF (Table 3). Of those variants the heterozygous missense variants have been reported to be implicated in PS, GD, ASD and sudden unexpected death in epilepsy, suggesting the role of SCARB2 gene in those disease mechanisms. Even though some of the reported biallelic pathogenic variants have not been reported to be associated with AMRF, given the observed clinical characteristics carriers of those might have been clinically misdiagnosed.

Symptomatic therapeutic interventions for the AMRF include targeting the neurological and renal manifestations. In general, Valproic acid, Clonazepam and Levetiracetam are administered against the neurological manifestations, dialysis and renal transplantation performed against the renal manifestations. Miglustat as a new therapeutic approach, which is an inhibitor of glucosylceramide synthase, has also been experienced in the clinical practice. However, even though miglustat treatment has been reported to be effective by reducing the myoclonic jerks in a patient with AMRF by Chaves et al. [38] and by improving dysphagia and other associated symptoms without any side effects by Quraishi et al. [27], other independent studies suggested that the treatment caused several side effects, such as nausea, vomiting and severe diarrhea [9, 25] and was therefore discontinued. Miglustat treatment was also administered to our two affected individuals (family1; II.8, II.12). Both patients could also not tolerate miglustat even at lower doses, due to severe exacerbation of action myoclonus and ataxia. The siblings with mild neurological presentation (family 1; II.10, II.13) unfortunately refused to start miglustat treatment in early stage of the disease, and no information about a possible positive effect on disease progression could be evaluated. However, given the reported number of patients not tolerating this treatment, further administration needs to be planned carefully.

Mainly renal manifestations of SCARB2 associated clinical picture include FSGS, or membranous nephropathy without storage [1, 25, 39]. Treatment of renal failure in AMRF patients is supportive. Renin-angiotensin blockage can prevent hyperfiltration, and proteinuria, and dialysis treatment is supposed to extend the life expectancy [39, 40], however, the neurological findings do not improve with dialysis. In our study the renin-angiotensin blockage decreased the proteinuria and slowed the progression of the end-stage renal disease in the individual II.8.

In our study WES analysis revealed a homozygous truncating variant (c.134delA; p.N45MfsX88) in the index case and subsequent sanger sequencing analysis confirmed the co-segregation of the variant with the disease. This is the second report describing the same pathogenic variant (c.134delA; p.N45MfsX88) in SCARB2 gene from Turkey, thus suggesting a possible founder affect. As a result of comparison with the family 2, intra and interfamilial clinical heterogeneity was observed with some common features with slightly different AO and distinct features, such as dysarthria and cognitive decline.

Similar clinical heterogeneity with a wide spectrum of neurological and renal symptoms was observed in all SCARB2 pathogenic variant carriers. Among the reported variants only the one (p.G462DelfsX34) localized in the C terminal site of the LIMP-2 has been statistically found to be associated with later onset of the disease.

SCARB2 is an important gene with an essential function in pathogenic mechanisms that are important in AMRF, GD, and PD. Therefore, genetic and functional studies to understand common and distinct mechanisms underlying all those three diseases have a great importance. So far it has been suggested that disrupted binding of LIMP-2 and GC does not necessarily have an impact on the disease pathogenesis and GC activity might be different in different cells probably based on the expression levels of the genes or the effect of the different modifiers. (Fig. 2). Nevertheless, further questions such as, which modifiers play a role in those pathways (Fig. 2) and why only some of the specific systems, such as brain and kidney, are particularly vulnerable (Fig. 2), remain elusive. Therefore, patients-specific induced pluripotent stem cell-based studies might be in the future the most promising way to contribute the best to the understanding of the SCARB2 related pathology in the related disease mechanisms.

**Abbreviations**

AMRF: Action myoclonus-renal failure syndrome; WES: Whole exome sequencing; AO: Age at onset; PD: Parkinson’s disease; GD: Gaucher disease; SCARB2: Scavenger receptor class B member 2; LIMP-2: Lysosomal integral membrane protein type 2; GC: β-Glucocerebrosidase; ER: Endoplasmic reticulum; MRI: Magnetic resonance imaging; NCV: Nerve conduction velocity; SEP: Somatosensory evoked potentials; EEG: Electroencephalography; FSGS: Focal segmental glomerulosclerosis; EMG: Concentric needle electromyography; PNP: Peripheral neuropathy; CT: Cytoplasmic; TM: Transmembrane.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12883-022-02628-y.

**Additional file 1.**  
**Additional file 2.**  

**Acknowledgements**

The authors thank all the patient and their family. Meltem Pak and Ebru Özer helped with obtaining samples.
Authors’ contributions
Burcu Atasu and Ayse Nur Ozdag Acarli contributed equally to this work as the first authors. Study concept and design: EL. Acquisition of data: ANOA, BB, BB. Analysis and interpretation of data: BA, ANOA, BB, ED, AKH. Drafting of the manuscript: BA ANOA, BB. Critical revision of the manuscript for important intellectual content: EL, BB, TG. Study supervision: EL, BB, YO, AT, HH, HG, ME, TG. All authors have read and approved the final version of the manuscript.

Funding
The work was supported by the funding of Deutsche Forschungsgemeinschaft (DFG): Project GA 402/25–1 | LO 2046/2–1. The funders did not play any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study has been approved by the local Institutional Review Board of the Medical Faculty of the University of Tübingen, Germany (vote 366/2018BO2) and by the Ethics Committee of Istanbul University, Turkey (vote 4513048/162). Written informed consent was obtained from all the individuals in this study. Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declares that they have no competing interests.

Author details
1 Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. 2 German Center for Neurodegenerative Diseases (DZNE)-Tübingen, Tübingen, Germany. 3 Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 4 Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 5 Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. 6 Division of Nephrology, Department of Internal Medicine, Koc School of Medicine, Koc University, Istanbul, Turkey. 7 Institute for Experimental Medicine, Genetics Department, Istanbul University, Istanbul, Turkey.

Received: 17 November 2021 Accepted: 9 March 2022
Published online: 28 March 2022

References
1. Andermann E, Andermann F, Carpenter S, Wolfe LS, Tafti S, Poizat V. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-gluco cerebroside. Cell. 2007;131(4):770–83.
2. Berkovic SF, Dibbens LM, Oshlack A, Silver JD, Katerelos M, Vears DF, Limpelmann-Rauch R, Blanz J, Kwok J, Stankovich J, Kalinos RM, Dowling JP, Andermann E, Andermann F, Faldini E, D’Hoore V, Vanlommel L, Macdonall RA, Hodgson BL, Bayly MA, Savige J, Mulley JC, Smyth GK, Power DA, Tafti P Bahlo M. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulocarcinosis. Am J Hum Genet. 2008;82(3):673–84.
3. Blanz J, Groth J, Zachos C, Wehling C, Tafti P, Schwake M. Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-gluco cerebroside. Hum Mol Genet. 2010;19(4):563–72.
4. Balraie A, Gaspar P, Caiafa D, Chavez J, Beirao L, Lima JL, Azevedo JE, Miranda MC. A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Mol Genet. 2008;17(14):2289–34.
5. Atasu B, Hanagasi H, Bilgic B, Park M, Erginel-Unaltuna N, Hauser AK, Guven G, Smön-Sánchez J, Heutink P, Gasser T, Lohmann E. HPCA confirmed as a genetic cause of DYT2-like dystonia phenotype. Mov Disord. 2018;33(8):1354–8.
6. Uçan Tokuy F, Genç F, Erdal A, Binçer GY. Report of two siblings with action myoclonus renal failure syndrome. Seizure. 2021;188(March):73–4.
7. Sterren PJ, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2014;133(1):1–9.
8. Daradis A, Filocamo M, Grossi S, Ciama G, Franceschetti S, Dominissini S, et al. Biochemical and molecular findings in a patient with myoclonic epilepsy due to a missense of the beta-gluco cerebrosidase enzyme. Med Genet Metab. 2009;97:309–11.
9. Dibbens LM, Michelucci R, Gambardella A, Andermann F, Rubboli G, Bayly MA, Joensuu T, Vears DF, Franceschetti S, Canafoglia L, Wallace R, Bassuk AG, Power DA, Tassinari CA, Andermann E, Lehesjoki AE, Berkovic SF. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann Neurol. 2009;66(4):532–6.
10. Dibbens LM, Karakis I, Bayly MA, Costello DJ, Cole AJ, Berkovic SF. Mutation of SCARB2 in a patient with progressive myoclonus epilepsy and demyelinating peripheral neuropathy. Arch Neurol. 2011;68(6):812–3.
11. Hopfner F, Schormair B, Knaff F, Berthele T, Teorre TR, Baron R, Maier C, Treadee RD, Binder A, Sommer C, Maihöfner CKunz W, Zimprich F, Heemann U, Pfeuffer A, Năbăuer M, Kălbă S, Nowak B, Gieger C, Lichter P, Tenkvalder C, Oxeke K, Winkelmann J. Novel SCARB2 mutation in action myoclonus-renal failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features. BMC Neurol. 2011;11:34.
12. Perandones C, Micheli FE, Pellenne LA, Bayly MA, Berkovic SF, Dibbens LM. A case of severe hearing loss in action myoclonus renal failure syndrome resulting from mutation in SCARB2. Mov Disord. 2012;27(9):1201–00.
13. Guerrero-López R, García-Ruiz PJ, Giráldez BG, Durán-Herrera C, Querol-Pascual MR, Ramírez-Moreno JM, Más S, Serratos JM. A new SCARB2 mutation in a patient with progressive myoclonus ataxia without renal failure. Mov Disord. 2012;27(14):1826–7.
14. Hishigahyama Y, Doi H, Wakabayashi M, Tsursukai Y, Miyake N, Saito S, Ohba C, Fukui R, Miyatake S, Joki H, Koyano S, Suzuki Y, Tanaka F, Kuriwasa Y, Matsumoto M. A novel SCARB2 mutation causing late-onset progressive myoclonus epilepsy. Mov Disord. 2013;28(4):552–3.
15. Fu YJ, Aida I, Tada M, Tada M, Toyoshima Y, Takeda S, Nakajima T, Naito H, Nishizawa M, Onodera O, Kakita A, Takahashi H. Progressive myoclonus epilepsy: extraneuronal brown pigment deposition and system neurodegeneration in the brains of Japanese patients with novel SCARB2 mutations. Neuropathol Appl Neurol. 2014;40(5):551–63.
16. Zeigler M, Meiner V, Newman JP, Steinner-Birman J, Bargal R, Surly V, et al. A novel SCARB2 mutation in progressive myoclonus epilepsy indicated by reduced β-glucocerebroside activity. J Neurosci. 2013;33:210–3.
17. He M, Tang BS, Li N, Mao X, Li J, Zhang JG, Xiao JJ, Wang J, Jiang H, Shen L, Guo JF, Xia K, Wang JL. Using a combination of whole-exome sequencing and homozygosity mapping to identify a novel mutation of SCARB2. Clin Genet. 2014;86(6):598–600.
18. He JI, Lin H, Li J, Su HZ, Wang DW, Lin Y, Wang N, Chen WJ. Identification of a Novel Homozygous Spike-Site Mutation in SCARB2 that Causes Progressive Myoclonus Epilepsy with or without Renal Failure. Chin Med J (Engl). 2018;131(13):1575–83.
22. Tian WT, Liu XL, Xu YQ, Huang XJ, Zhou HY, Wang Y, Tang HD, Chen SD, Luan XH, Cao L. Progressive myoclonus epilepsy without renal failure in a Chinese family with a novel mutation in SCARB2 gene and literature review. Seizure. 2018;57:80–6.

23. Hotatt M, Dirani M, El Halabi T, Beydoun A. Case Report Distinctive EEG Patterns in SCARB-2 Related Progressive Myoclonus Epilepsy. Front Genet. 2020;11:58123.

24. Doherty KM, Shields J, Forbes R, Gray M, Kearney S, Maxwell AP, McKinley J. A Rare Cause of Myoclonus: A Cupric Conundrum. JAMA Neurol. 2016;73(9):1145–8.

25. Desbuissous G, Brocheriou I, Touchard G, Goujon JM, Ménéeret A, Isnard-Bagnis C. Renal Pathological Findings in Action Myoclonus-Renal Failure Syndrome. Nephron. 2020;144(2):55–8.

26. Yari A, Al-Nejad RM, Saleh-Gohari N. A novel homozygous splice-site mutation in SCARB2 is associated with progressive myoclonic epilepsy with renal failure. Neurol Sci. 2021;42(12):5077–85.

27. Qurarsi IH, Szekely AA, Shirah AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus-Renal Failure Syndrome. Neuror Genet. 2021;7(5):e614.

28. Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21.

29. Friedman D, Kanani K, Faustini A, Shroff S, Thomas C, Heguy A, Serrano J, Snuderl M, Devinsky O. Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). NPU Genom Med. 2018;27(3):9.

30. Chow YP, Abdul Murad NA, Mohd Rani Z, Khoo JS, Chong PS, Wu LL, Jamal R. Exome sequencing identifies SLC26A4, GJB2, SCARB2 and DUOX2 mutations in 2 siblings with Pendred syndrome in a Malaysian family. Orphanet J Rare Dis. 2017;12(1):40.

31. Lindy AS, Stosser MB, Butler E, Dowtain-Pickersgill C, Shammugaham A, Retterer K, Brandt T, Richard G, McKnight DA. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 2018;59(5):1062–71.

32. Velayati A, DePaolo J, Gupta N, Moaven N, Westbrook W, Goker-Alpan O, Golden E, Stubblefield BK, Kolodny E, Tayebi N, Sidransky E. A mutation in SCARB2 is a modifier in Gaucher disease. Hum Mutat. 2011;32(11):1232–8.

33. Gonzalez A, Valeiras M, Sidransky E, Tayebi N. Lysosomal integral membrane protein-2: a new player in lysosome-related pathology. Mol Genet Metab. 2014;111(2):84–91.

34. Jian J, Tian QY, Hettinghouse A, Zhao S, Liu H, Wei J, Gru nig G, Zhang W, Setchell KDR, Sun Y, Overkleeft HS, Chan GL, Liu C. Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease. EBioMedicine. 2016;3:212–24.

35. Gamp AC, Tanaka Y, Lüllmann-Rauch R, Wittke D, D'Hooge R, De Deyn PP, Hartmann D, Reiss K, Illert AL, von Figura K, Saftig P. LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum Mol Genet. 2003;12(6):631–46.

36. Chaves J, Beirão I, Balreira A, et al. Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: Clinical report of two siblings. Seizure. 2011;20(9):738–40.

37. Neild GH. Life expectancy with chronic kidney disease: an educational review. Pediatr Nephrol. 2017;32(2):243–8.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.